#151039

Anti-Integrin aVb3 [23C6]

Cat. #151039

Anti-Integrin aVb3 [23C6]

Cat. #: 151039

Sub-type: Primary antibody

Unit size: 100 ug

Availability: 3-4 weeks

Target: Integrin alpha V B3 (CD51/61; Osteoclast Fn Antigen)

Class: Monoclonal

Application: FACS ; IHC ; IP ; Fn

Reactivity: Human

Host: Mouse

£300.00

This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.

Contributor

Inventor: Mike Horton

Institute: Queen Mary University of London

Primary Citation: Horton et al. 1985. Cancer Res. 45(11 Pt 2):5663-9. PMID: 4053038.

Tool Details
Target Details
Applications
Handling
References

Tool Details

*FOR RESEARCH USE ONLY

  • Name: Anti-Integrin aVb3 [23C6]
  • Research fields: Cancer;Cell biology;Tissue-specific biology
  • Clone: 23C6
  • Tool sub type: Primary antibody
  • Class: Monoclonal
  • Conjugation: Unconjugated
  • Molecular weight: 125/124 kDa, 150 kDa
  • Strain: Balb/c
  • Reactivity: Human
  • Host: Mouse
  • Application: FACS ; IHC ; IP ; Fn
  • Description: 23C6 reacts with the alpha V/beta 3 integrin (CD51/CD61). 23C6 may be useful for bone resorption modulation, osteoclast identification, receptor purification, malignant melanoma identification and treatment.
  • Immunogen: A cell suspension containing osteoclasts from osteoclastomas.
  • Isotype: IgG1
  • Myeloma used: P3X63Ag8.653
  • Recommended controls: Tonsil

Target Details

  • Target: Integrin alpha V B3 (CD51/61; Osteoclast Fn Antigen)
  • Molecular weight: 125/124 kDa, 150 kDa
  • Tissue cell line specificity: Tonsil
  • Target background: Integrins are heterodimeric cell surface receptors composed of alpha and beta subunits, which mediate cell-cell and cell-extracellular matrix attachments. Aberrant integrin expression has been found in many epithelial tumours. Changes in integrin expression have been shown to be important for the growth and early metastatic capacity of melanoma cells. Integrin alpha V associates with integrin beta3 to form the osteoclast Fn antigen (vitronectin receptor). Integrin alpha V is found in osteoclasts, placenta, melanoma cell lines and some epithelial cell lines. Expression of integrin alpha V increases with melanoma progression.

Applications

  • Application: FACS ; IHC ; IP ; Fn

Handling

  • Format: Liquid
  • Concentration: 1 mg/ml
  • Unit size: 100 ug
  • Storage buffer: PBS with 0.02% azide
  • Storage conditions: -15° C to -25° C
  • Shipping conditions: Shipping at 4° C

References

  • Chetty et al. 2010. Int J Cancer. 127(5):1081-95. PMID: 20027628.
  • Martino et al. 2009. Biomaterials. 30(6):1089-97. PMID: 19027948.
  • Zhou et al. 2006. J Exp Med. 203(4):1067-80. PMID: 16606672.
  • Marshall et al. 1995. J Cell Sci. 108 ( Pt 3):1227-38. PMID: 7542669.
  • Horton et al. 1985. Cancer Res. 45(11 Pt 2):5663-9. PMID: 4053038.